Kytril

By G. Runak. South Pacific University.

Why are we not screening for anal cancer routinely – HIV physicians’ perspectives on anal cancer and its screening in HIV-positive men who have sex with men: a qualitative study buy cheap kytril 1 mg line. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia order kytril 1 mg amex. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors buy generic kytril 2mg line. Anal cancer prevention in HIV-positive men and women. Pantanowitz L, Bohac G, Cooley TP, Aboulafia D, Dezube BJ. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. Outcome of patients with HIV-related germ cell tumours: a case-control study. Relationship between current level of immunodeficiency and non-acquired immun- odeficiency syndrome-defining malignancies. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Treatment of Anal Intraepithelial Neoplasia in HIV+ MSM: A Triple-arm Randomized Clinical Trial of Imiquimod, Topical 5-Fluoruracil, and Electrocautery. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Age at cancer diagnosis among persons with AIDS in the United States. Cancer Burden in the HIV-Infected Population in the United States. HIV as an independent risk factor for incident lung cancer. Risk of cancers during interrupted antiretroviral therapy in the SMART study. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Primary esophageal carcinoma in the era of highly active antiretroviral therapy. Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an AIDS malignancy consortium pilot study. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. Progression to and spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men. Review of screening guidelines for non-AIDS-defining malignancies: evolving issues in the era of highly active antiretroviral therapy. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. Non-AIDS defining cancers in the D:A:D Study—time trends and predictors of survival: a cohort study. HIV and HBV/HCV Coinfections CHRISTOPH BOESECKE, JAN-CHRISTIAN W ASMUTH AND JÜRGEN K. ROCKSTROH HIV and HCV coinfection Epidemiology and Transmission Coinfection with HIV and HCV occurs frequently, due to the fact that they are trans- mitted via the same pathways (parenteral, sexual, vertical). In the US about 25% of HIV+ individuals are estimated to be infected with both viruses. Several European countries have even higher rates of coinfection (Rockstroh 2005). In Russia, about 70% of the 940,000 HIV+ patients are also HCV-positive as a result of the high inci- dence of IV drug users. Needle exchange programs have resulted in a marked decline in new infections of HCV in Western Europe. For example, in Barcelona the preva- lence of HCV coinfection in persons with newly diagnosed HIV-infection has decreased from 24% during 2000–2002 to 10% in 2006–2008 (Trevino 2009). HCV is ten times more infectious than HIV via blood-to-blood contact. Intravenous drug users and recipients of blood products are particularly susceptible to coinfec- tion. Nevertheless, the probability of transmission from occupational needlestick injuries after exposure to HCV-contaminated blood is less than 2%, possibly even lower; i. In contrast, sexual transmission of HCV occurs significantly less frequently than HBV or HIV (risk of transmission via heterosexual intercourse is <1%). About 4–8% of all HIV+ men who have sex with men (MSM) are also infected with HCV. The first cases of acute hepatitis C among HIV+ MSM were observed in London, Paris, Amsterdam and Berlin but have spread to a worldwide epidemic over the last decade (Boesecke 2015). The risk of transmission depends on concomitant sexually transmitted dis- eases such as syphilis or lymphogranuloma venereum, performance of sexual prac- tices that are prone to injuries of the mucosal membranes like fisting or intensive repetitive anal sex, and intravenous use of recreational drugs (“Chem sex”) (Vogel 2005, GMFA 2013). Perinatal transmission of hepatitis C is rare in immunocompetent individuals (<1%). The transmission rate rises with increasing immunosuppression in HIV+ mothers, and is estimated to be as high as 20%. On the other hand, HIV+ mothers treated effectively with antiretroviral therapy do not appear to have an increased risk for materno-fetal transmission of the hepatitis C virus (<3% with cesarean section) (Pembrey 2005). Cesarean section did not reduce the risk of transmission to the newborn of HCV-monoinfected women putting the role of cesarean section into question (Indolfi 2009). Clinical course and pathogenesis The clinical course of hepatitis C and HIV coinfection is determined by HIV-associ- ated immunosuppression. Progression of immunosuppression accelerates the course of hepatitis C. Conversely, there is no significant influence of hepatitis C on the course of HIV infection (Rockstroh 2005). The latent period until development of liver failure or hepatocellular carcinoma in coinfected patients is estimated to be 10–20 years, whereas it is 30–40 years in HCV-monoinfected patients (Benhamou 1999). Improved treatment options for HIV infection have increased the likelihood of patients actually living to experience the development of liver failure which has become at least in some centers a frequent cause of death (Rosenthal 2007).

The investigators con- High-dose cytarabine and ASCT cluded that HiDAC is a key component of initial therapy for eligible Several lines of evidence support an important role for high-dose MCL patients and that ASCT in CR1 is a current standard of care buy kytril 2mg otc, a cytarabine (HiDAC) in prolonging initial treatment response cheap 2mg kytril visa, if not position supported by National Comprehensive Cancer Network OS purchase kytril uk. A single-institution study of R-HyperCVAD (rituximab frac- 2013 recommendations and by the European Society for Medical tionated cyclophosphamide vincristine, doxorubicin, and dexa- Oncology 2013 Consensus Conference. However, multicenter trials have found lower remission are well-established in CML and acute lymphocytic responses and high toxicity rates, with more than one-third of leukemia as important determinants of patient outcome and as a patients unable to complete the planned therapy. To date, MRD testing is not fully established in current U. Intergroup trial (SWOG 1106) of R-HyperCVAD/MTX- MCL, lacking both standardized methodology and availability AraC versus R-bendamustine followed by ASCT was closed outside of clinical trials. However, achievement of molecular recently due to an impaired ability to collect sufficient stem cells remission was an independent and very strong predictor of clinical from patients in the R-HyperCVAD arm. Given the toxicity of this outcome in the MCL Younger Trial described above and in the regimen and the need for inpatient chemotherapy administration European MCL Network Elderly Trial of frontline immunochemo- (and frequently for management of cytopenic or other treatment- therapy (see “Treatment of MCL in non-SCT-eligible patients” associated complications), alternative HiDAC-containing regimens below). In the MCL Younger Trial, peripheral blood and BM samples were R-DHAP (R dexamethasone, HiDAC, cisplatinum) showed a obtained at baseline and at various time points during induction CR/unconfirmed CR rate of 76% in 199 untreated MCL patients therapy, pre- and post-ASCT, and during follow-up. MRD analysis after 4 cycles of therapy, with most then proceeding to ASCT. After induction Belgian Groupe d’Etude des Lymphomes de l’Adulte (GELA) therapy, BM MRD negativity was significantly greater in the conducted a phase 2 trial of 60 previously untreated patients 66 R-CHOP/R-DHAP–treated patients (68%) versus those treated with years of age with advanced MCL using R-CHOP 3 cycles R-CHOP (24%). ASCT improved MRD BM negativity to 65% of followed by 3 cycles of R-DHAP. A total of 93% of patients patients for R-CHOP and 88% for R-CHOP/R-DHAP, verifying a responded to R-CHOP, but only 12% achieved CR. This increased benefit for ASCT consolidation in deepening remission. With a median follow-up of 67 months, the molecular remission in the peripheral blood during the first year 5-year OS is 75%. No myelodysplastic syndrome or acute after ASCT was correlated with improved time to treatment failure myeloid leukemia events were reported, although there was a and a 2-year PFS of 90%. MRD status was the strongest surprisingly high rate of second cancers (11 patients, 5 with renal independent predictor of outcome in this trial and was superior to cell carcinoma). Although no clear standard of care exists for those patients requiring therapy, the accepted approach until recently has been immunoche- motherapy induction followed by observation and sequential treat- ment of relapsing disease. The proteasome inhibitor bortezomib and the immunomodulatory agent lenalidomide are approved for re- lapsed disease in the United States, whereas the mammalian target of rapamycin (mTOR) inhibitor temsirolimus is approved in the European Union. Several clinical trials have explored the integra- tion of these agents concomitantly with R-CHOP or R-bendamus- tine and as consolidative therapy, but these approaches remain investigational. R-CHOP has been the most widely used regimen in MCL, but median response durations have been on the order of 18 to 24 Figure 1. Response duration according to MRD status in peripheral months only. The high activity of bendamustine in relapsed MCL blood and/or BM after induction immunochemotherapy in the led to a German multicenter phase 3 noninferiority trial comparing European MCL Younger Trial. Treatment consisted of standard R-CHOP-21 versus benda- therapy thus holds strong promise for predicting outcome and for mustine 90 mg/m2 on days 1 and 2 of each 28-day cycle, with modifying patient management, such as the use of rituximab standard-dose R on day 1. A total of 46 MCL patients were “preemptive therapy” for molecular relapse to reinduce remission. Lower toxic- processing, and molecular methods will be necessary. In addition, ity was observed for R-B, including significantly less grade 3-4 prospective testing to validate treatment intervention based upon neutropenia despite less frequent use of G-CSF, as well as fewer MRD results will be essential. R-B is now accepted as a frontline regimen for MCL What is the role of allogeneic SCT? However, only a minority of patients are eligible due to the 60 years of age. It is The multicenter phase 3 MCL Elderly Trial compared R-CHOP- not recommended as part of frontline therapy or consolidation 21 8 cycles with R-fludarabine plus cyclophosphamide (R-FC) outside of a clinical trial. Retrospective single- and multi- every 28 days 6 cycles as induction therapy for non-SCT-eligible institutional reviews have shown durable PFS of 14% to 46% and patients age 60 or older with previously untreated MCL. Respond- OS of 37% to 53%, with evidence of a plateau in the survival curve ing patients underwent a second randomization to thrice-weekly suggesting cure. A beneficial effect of donor lymphocyte infusion was docu- was continued until disease progression or toxicity. A total of 532 mented in some relapsing patients, consistent with a GVL effect. The ORR after induction therapy was ASCT and multiple lines of prior therapy. Four-year OS was An analysis from the Center for International Blood and Marrow significantly poorer with R-FC (47%) versus R-CHOP (62%; Transplant Research database identified 202 patients with treatment- P. More patients progressed during therapy with R-FC refractory MCL who underwent myeloablative (n 74) or reduced- (14% vs 5%) and more patients died of lymphoma, infection, or intensity conditioning/nonmyeloablative transplantations (n 128). A significant benefit There were no significant differences between the conditioning was observed for both PFS and OS for maintenance R after regimens at 3 years, with nonrelapse mortality at 43% to 47%, R-CHOP (but not R-FC) compared with maintenance IFN-. The relapse or progression in 32% to 33% of patients, PFS 20% to 25%, investigators concluded that R-CHOP followed by maintenance R is and OS 25% to 30%. Higher mortality was observed with the use of an effective regimen for older, non-SCT-eligible patients. BM as the stem cell source or with T-cell–depleted grafts. Maintenance therapy: evolving options The option of allogeneic SCT should always be addressed in a R-CHOP followed by maintenance R in the MCL Elderly study younger, otherwise healthy individual at the time of first relapse or showed that the median remission duration was not reached at 36 disease progression, including those with prior ASCT, as the only months median follow-up compared with 23 months for patients established curative approach. Chemosensitive patients appear to receiving IFN- maintenance, the latter very similar to prior have better outcomes. The use of one or more of the novel published reports of remission duration with R-CHOP alone. At a therapeutic agents described below as a bridge to allogeneic SCT median follow-up for OS of 42 months, there was a significant also appears promising and may lower the non-treatment-related benefit for R maintenance, with median OS not reached, versus 64 mortality associated with traditional cytotoxic salvage regimens. Kenkre et al22 used 570 American Society of Hematology modified R-HyperCVAD induction therapy (without methotrexate Table 1. Selected novel agents for treatment of MCL or cytarabine) in 22 non-SCT-eligible patients. Induction therapy Pathway/ was followed in those patients achieving CR or partial remission mechanism Agent Proposed targets (PR) by maintenance R administered weekly 4 doses every 6 months for 2 years. With a median follow-up of 62 months, the Immunomodulatory Lenalidomide Tumor microenvironment, cytokine loops, median PFS was 37 months and the median OS 70 months, with no proliferation, late toxicities. The response durations in these trials thus compare angiogenesis favorably with those after SCT consolidation, although prospective BCR signaling Idelalisib (GS1101; PI3K comparison will be necessary to discern the relative benefit and CAL-101) safety of these 2 postinduction approaches. Ibrutinib (PCI-32765) BTK; CXCR4 Fostamatinib SYK The immunomodulatory agent lenalidomide has single-agent activ- Enzastaurin PKC ity in relapsed or refractory MCL, including patients treated with Temsirolimus, mTOR prior bortezomib, and has been approved for this indication by the everolimus Food and Drug Administration (FDA).

Studies conducted at the Hematology 2013 391 City of Hope by Zaia and Rossi demonstrated that cord blood units for HIV-1-associated lymphoma cheap kytril master card. Autologous stem cell transplantation could be used to engraft HIV-resistant cells discount 1mg kytril fast delivery. Krishnan A purchase kytril 1mg with mastercard, Palmer JM, Zaia JA, Tsai N-C, Alvarnas J, Forman recently received transplantation at the University of Minnesota SJ. HIV status does not affect the outcome of autologous stem with a cord blood unit identified to be CCR5 double mutant; cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). The emerging data and clinical trials in patients with HIV infection 9. High-dose therapy and suggest that transplantation of autologous gene-modified cells has autologous peripheral blood stem cell transplantation as salvage the potential to alter the relationship between the virus and the treatment for AIDS-related lymphoma: long-term results of the human host, modifying the natural history of the disease and Italian Cooperative Group on AIDS and Tumors (GICAT) possibly reducing or eliminating the need for antiretroviral drugs to study with analysis of prognostic factors. Autologous stem-cell immunocompetence and possibly mediate antiretroviral immune transplantation in patients with HIV-related lymphoma. A complete cure for the disease such that patients Oncol. High-dose therapy plus require elimination of both the infected T cells and the reservoir of autologous hematopoietic stem cell transplantation for human virus in the body. Emerging studies in allogeneic recipients will immunodeficiency virus (HIV)-related lymphoma: results and help to determine whether a naturally occurring or engineered impact on HIV disease. Plasma viremia and Correspondence cellular HIV-1 DNA persist despite autologous hematopoietic Stephen J. Forman, MD, Chair, Department of Hematology and stem cell transplantation for HIV-related lymphoma. J Acquir Hematopoietic Cell Transplantation, City of Hope Comprehensive Immune Defic Syndr. Cancer Center, 1500 E Duarte Road, Duarte, CA 91010; Phone: 15. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34 cells. Stable reduction of immunodeficiency virus infection. Positive selection of the era of highly active antiretroviral therapy. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, 179-187. High-dose undergoing hematopoietic stem cell transplantation: a prospec- therapy and autologous hematopoietic stem-cell transplantation tive evaluation of pharmacokinetic and pharmacodynamic 392 American Society of Hematology profile with therapeutic drug monitoring. Generation of stem/progenitor cells modified by zinc-finger nucleases tar- HIV-1-specific CD8 cell responses following allogeneic geted to CCR5 control HIV-1 in vivo. Reduced-intensity conditioning HIV-1 coreceptor CCR5 in adult hematopoietic stem and allogeneic stem cell transplantation in HIV patients with progenitor cells using zinc finger nucleases. Long-term reduction in transplantation, zidovudine, and human immunodeficiency vi- peripheral blood HIV-1 reservoirs following reduced-intensity rus type 1 (HIV-1) infection: studies in a patient with non- conditioning allogeneic stem cell transplantation. Hematopoietic Cell plantation in patients with human immunodeficiency virus: the Transplantation with Cord Blood for Cure of HIV Infections. Gonzalez G, Park S, Chen D, Armitage S, Shpall E, Behringer 25. Identification and frequency of CCR5Delta32/Delta32 HIV- poietic cell transplantation in human immunodeficiency virus- resistant cord blood units from Houston area hospitals. HIV positive patients with hematologic disorders: a report from the Med. Mackall1 1Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD Substantial progress has been made in the treatment of precursor B-cell acute lymphoblastic leukemia (B-ALL), but recurrent disease remains a leading cause of death in children due to cancer and outcomes for adults with B-ALL remain poor. Recently, complete clinical responses have been observed in small numbers of patients with B-ALL treated with adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule present in essentially all cases of B-ALL. Preclinical data suggest that CARs targeting CD22, another antigen present in the majority of B-ALL cases, are similarly potent. Several clinical studies already under way will soon more clearly define the rate of response to this novel therapy in B-ALL. Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable. Introduction treatment of B-ALL over recent decades, outcomes remain poor for Approximately 5000 to 6000 new cases of precursor B-cell acute several subgroups and we have likely reached a point of diminishing lymphoblastic leukemia (B-ALL) are diagnosed in the United States returns with increasing intensity of standard cytotoxic regimens. Modern multiagent regimens have resulted in impressive cure rates of almost 90% in children The modern era of genomics has identified several potential with B-ALL,1 yet due to its relatively high incidence compared with molecular targets in B-ALL and the addition of bcr-abl inhibitors to other childhood cancers, B-ALL remains a leading cause of death in standard cytotoxic regimens in Philadelphia chromosome–positive children due to cancer. Risk stratification based on clinical features, ALL markedly improve the outcome in this high-risk subgroup. However, outcomes with chemotherapy alone of pathways that contribute to oncogenesis in this disease. Furthermore, even modern emerging picture of B-ALL oncogenesis suggests that effective risk-adapted strategies require prolonged treatment regimens with targeting of B-ALL using small-molecule tyrosine kinase inhibitors substantial long-term morbidity. Another approach to improving outcomes is to target cell surface molecules using mAb-derived therapeutics. Improvements in survival have also been achieved in other age Unconjugated mAbs targeting CD20 have had impressive effects groups, but with declining success with increasing age (5-year when combined with cytotoxic regimens in CD20 B-cell malignan- overall survival rates of 60% for ages 15-20 and 45% for ages cies, although expression of CD20 in pediatric B-ALL is limited to 20-30 years). For adults older than 30 years at the time of diagnosis, the Burkitt subtype, which represents a minority of cases presenting overall survival is estimated to be 20% to 40%. Interestingly, recent studies have suggested higher indicate that the use of more intensive pediatric regimens in adults rates of CD20 expression in relapsed B-ALL with improved can improve outcomes somewhat,4 but the high-risk features outcomes reported in adults 60 years of age with de novo CD20 associated with B-ALL in adults makes it unlikely that the successes ALL (defined as expression on 20% of the blast population) when seen in children will be achieved with currently available regimens. Allogeneic hematopoietic stem cell antitumor effects10; however, bispecific anti-CD19 mAbs that transplantation (allo-HSCT) leads to cure in 50% of patients who simultaneously bind a cell surface antigen on B-ALL and CD3 on achieve second complete remission. As a result, data in directly without activating endogenous immune effectors. This ap- which all relapses are included in the analysis irrespective of proach has seen increasing success, including recent studies using an whether allo-HSCT is performed show a much more dismal overall anti-CD22 mAb-derived binding domain plus a Pseudomonas-derived survival for patients with relapsed ALL, despite intensive, highly exotoxin that demonstrate clinical responses in a substantial fraction of toxic therapy. Therefore, despite increasing success in the leukemia cell surface antigens has shown increasing promise. This 348 American Society of Hematology review focuses on this rapidly emerging field of adoptive therapy for costimulatory domains had improved persistence and efficacy B-ALL using immune cells genetically modified to express chime- compared with those expressing CD28 endodomains. In summary, there is a consensus that incorporation tion domain linked to an intracellular component that activates a of at least one costimulatory endodomain is essential for CARs to signaling cascade in the immune effector cell. In most cases, the mediate meaningful antitumor effects, but it remains unclear antigen-binding domain consists of single protein chains derived whether any costimulatory endodomain is superior to the others. The signaling component ister cells expressing either CD28 endodomains or 4-1BB endodo- has evolved greatly since the original description of a chimeric 16 mains, thus precluding direct comparison.

International Journal of Radiation Oncology Biology Physics order kytril 1mg free shipping. Ondansetron versus placebo for prophylaxis of nausea and vomiting in patients undergoing ambulatory laparoscopic 2 cholecystectomy order 1 mg kytril fast delivery. Ondansetron decreases emesis after 2 tonsillectomy in children discount kytril 1mg fast delivery. Lopez-Olaondo L, Carrascosa F, Pueyo FJ, Monedero P, Busto N, Saez A. Combination of ondansetron and dexamethasone in the prophylaxis of 2 postoperative nausea and vomiting. Prevention of postoperative nausea and vomiting with metoclopramide, droperidol and ondansetron: A randomized, 2 double-blind comparison with placebo in ambulatory surgery. Nausea and vomiting after gynaecological laparoscopy: Comparison of premedication with oral 2 ondansetron, metoclopramide and placebo. The prevention of emesis in plastic surgery: A randomized, prospective study. Anti-emetic control with ondansetron in the chemotherapy of breast cancer: A review. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone 4 and methylprednisolone. Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing 2 ambulatory gynecologic surgery. A randomized, double blind pilot study examining the use of intravenous ondansetron in the prevention of 2 postoperative nausea and vomiting in female inpatients. Droperidol/ondansetron combination controls nausea and vomiting after tubal banding [published 2 erratum appears in Anesth Analg 1997 Mar;84(3):704] [see comments]. The antiemetic efficacy of prophylactic granisetron in gynecologic surgery. Antiemetics Page 121 of 136 Final Report Update 1 Drug Effectiveness Review Project Exclusion Excluded Studies code # Mikawa K, Takao Y, Nishina K, Shiga M, Maekawa N, Obara H. Optimal dose of granisetron for prophylaxis against postoperative emesis after 2 gynecological surgery. Efficacy of ondansetron and dexamethasone in the prevention of postoperative nausea and vomiting after 2 caesarean section. Single IV bolus dose of ondansetron in the prevention of postoperative nausea and emesis. International, multicentre, placebo- controlled study to evaluate the effectiveness of ondansetron vs 2 metoclopramide in the prevention of post-operative nausea and vomiting. Ondansetron reduces nausea and vomiting after paediatric adenotonsillectomy. Zofran (ondansetron) in preventing postoperative nausea and vomiting after laparoscopic 2 cholecystectomy. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double- 2 blind, randomized comparative trial of ondansetron versus placebo. Prevention of postoperative vomiting with granisetron in paediatric patients with and without a history of motion sickness. Effect of ondansetron hydrochloride on nasuea and vomiting after transcatheter arterial emboliza in 2 patients with hepatocellular carcinoma. A comparison of cyclizine, ondansetron and placebo as prophylaxis against postoperative nausea and vomiting in 2 children. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for 2 the control of cisplatin-induced delayed emesis. Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: Ondansetron versus 2 droperidol. Antiemetics Page 122 of 136 Final Report Update 1 Drug Effectiveness Review Project Exclusion Excluded Studies code # Pan PH, Moore CH. Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural 2 anesthesia. Comparing the efficacy of prophylactic metoclopramide, ondansetron, and placebo in cesarean section patients given epidural 2 anesthesia. Postoperative emesis 2 following otoplasty in children. Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, 2 droperidol, metoclopramide and placebo. Single dose intravenous ondansetron in the prevention of 2 postoperative nausea and vomiting. Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general 2 anaesthesia: A randomized, placebo-controlled study. Piper SN, Suttner SW, Rohm KD, Maleck WH, Larbig E, Boldt J. Dolasetron, but not metoclopramide prevents nausea and vomiting in patients undergoing 2 laparoscopic cholecystectomy. Piper SN, Triem JG, Maleck WH, Fent MT, Huttner I, Boldt J. Placebo- controlled comparison of dolasetron and metoclopramide in preventing 2 postoperative nausea and vomiting in patients undergoing hysterectomy. Pitkanen MT, Numminen MK, Tuominen MK, Rosenberg PH. Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting 4 after intrathecal morphine. Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. Principi F, Di Angelo P, Sofra M, Salerno S, Aloe L. Intravenous ondansetron in the prophylactic treatment of postoperative nausea and vomiting in 2 gynaecological surgery. Pueyo FJ, Carrascosa F, Lopez L, Iribarren MJ, Garcia-Pedrajas F, Saez A. Combination of ondansetron and droperidol in the prophylaxis of 2 postoperative nausea and vomiting. Droperidol-ondansetron combination versus droperidol alone for postoperative control of emesis after 2 total abdominal hysterectomy. Antiemetics Page 123 of 136 Final Report Update 1 Drug Effectiveness Review Project Exclusion Excluded Studies code # Rodjer S, Mercke C, van Imhoff G, et al. A randomized double-blind placebo controlled study of Ondansetron against CHOP-induced emesis. The effect of a 4-Mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after 2 maxillofacial surgery. Single pre- operative dose of ondansetron for nausea and vomiting following 2 maxillofacial surgery. Rodrigo MRC, Campbell RCH, Chow J, Tong CKA, Hui E, Lueveswanij S.